Search Filters
Advanced Search
SMC ID Date Medicine Submission Type Indication
SMC2925 11/05/2026 brentuximab (Adcetris) Non submission

Adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD).
SMC2762 11/08/2025 brentuximab vedotin (Adcetris) Full

Treatment of adult patients with previously untreated cell membrane receptor 30-positive (CD30+) Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).
SMC2310 18/01/2021 brentuximab vedotin (Adcetris) Full

In combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).
SMC2229 13/01/2020 brentuximab (Adcetris) Full

For the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
SMC2085 07/05/2018 brentuximab vedotin (Adcetris) Non submission Treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant.
1296/18 12/03/2018 pembrolizumab (Keytruda) Full monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.
1240/17 10/07/2017 nivolumab (Opdivo) Full For the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.
845/12 13/10/2014 brentuximab vedotin (Adcetris) Full For the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): 1. following autologous stem cell transplant (ASCT) or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

No medicines have been found.